REPL
Replimune Group, Inc.
Key Financials
Operating Income
$-319919000
↓ 22.3%
Net Income
$-313940000
↓ 26.9%
Revenue
$0
N/A
EPS (Diluted)
$-3.38
↓ 10.1%
Total Assets
$332.4M
↓ 39.7%
Shareholders' Equity
$166.2M
↓ 60.0%
Total Liabilities
$166.2M
↑ 22.7%
Cash & Equivalents
$209.0M
↑ 88.1%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| S-8 | 6/29/2026 | View on SEC |
| 10-K | 6/29/2026 | View on SEC |
| 8-K | 6/29/2026 | View on SEC |
| 8-K | 6/26/2026 | View on SEC |
| 4 | 6/3/2026 | View on SEC |
| 8-K | 5/29/2026 | View on SEC |
| SCHEDULE 13G | 5/21/2026 | View on SEC |
| 4 | 5/20/2026 | View on SEC |
| 4 | 5/20/2026 | View on SEC |
| 4 | 5/20/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | REPL |
| Company Name | Replimune Group, Inc. |
| CIK | 1737953 |
| Sector | Biological Products, (No Diagnostic Substances) |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2836 |
| SIC Description | Biological Products, (No Diagnostic Substances) |
| Entity Type | operating |
| Fiscal Year End | 0331 |
| State of Incorporation | DE |
| Phone | (781) 222-9600 |